M. Szarek

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.

J. Tardif, S. Ketchum, Michael Miller, 2024, Journal of the American College of Cardiology.

Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: ODYSSEY OUTCOMES

R. Pordy, M. Scemama, J. Mcginniss, 2024, Journal of Clinical Lipidology.

Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD

A. Odutayo, V. Sridhar, Deepak L. Bhatt, 2024, Clinical journal of the American Society of Nephrology : CJASN.

Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial

Ian A. Carroll, D. Morrow, M. Effron, 2023, Arteriosclerosis, thrombosis, and vascular biology.

Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.

A. Voors, J. Testani, A. Bhatt, 2024, Journal of the American College of Cardiology.

Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial

Deepak L. Bhatt, L. A. Leiter, Rahul Aggarwal, 2024, European journal of heart failure.